"We have completed a good fourth quarter with strong growth both as a result of the acquisition that we completed in July and an increase in demand for our products within antibiotics. We continue working on improving our gross margins, and I am pleased to see that we have achieved above 40 per cent in the quarter," says Kathrine Gamborg Andreassen, CEO of Navamedic.

The growth in the fourth quarter was driven by the addition of the acquired Addiction portfolio as well as a significant increase in sale of antibiotics to Nordic hospitals after recent tender wins during 2025. This translated into a growth for Prescription Drugs of 24.1 per cent in the quarter, and a growth for Hospital of 40.3 per cent in the quarter compared to the same quarter last year. Consumer Health saw a 6.6 per cent reduction in revenues in the fourth quarter compared to same quarter last year mainly due to periodization of campaign activities.

The growth for full-year 2025 of 6.4 per cent was largely due to strong growth within antibiotics and the impact from the acquired Addiction portfolio. The resulting growth in Hospital was 22.9 per cent in 2025, while Prescription Drugs and Consumer Health grew at 10.5 per cent and 2.3 per cent respectively.

Gross margin came in at 40.3 per cent in the quarter, a significant improvement from the result in the same period last year of 33.7 per cent. The full-year gross margin in 2025 was on par with last year at 39.0 per cent.

"We have managed to grow the company in 2025 without any large out-licensing milestones, and in a market for obesity products that has continued to be very competitive. With the full-year effect of the addiction portfolio and some growth in other product areas, I believe we should be able to continue a similar growth path in 2026. We will also work hard to stabilize our gross margins above 40 per cent," says Kathrine Gamborg Andreassen.

"The launch in December 2025 of Flexilev in OraFID for advanced Parkinson's care reflects our commitment to be a proud contributor to public health and was an important milestone in our growth plan, but the volume for this product will still be modest in 2026," says Kathrine Gamborg Andreassen.

Presentation and webcast

CEO Kathrine Gamborg Andreassen and CFO Nils Ole Krekling will present the results today at 08:30 CET at Haakon VIIs gate 2, Oslo, Norway. The presentation will be streamed live and available on demand via the following link: https://navamedic.com/investors/ 

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, mobile: +47 951 78 680
Nils Ole Krekling, CFO, mobile: +47 924 24 016

About Navamedic 
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.